Cibus Inc

Cibus Inc has a market capitalization of $114.42 million and a price-to-book ratio of 5.24, indicating that the market is valuing the company at a premium to its book value. The company's liquidity position is weak, with a current ratio of 0.72 and negative free cash flow of -$126.96 million. The company's cash and equivalents of $9.92 million are significantly lower than its long-term debt of $235.45 million, resulting in a debt-to-equity ratio of 10.79. Profitability metrics are deeply negative, with a return on equity of -5.82% and a return on assets of -0.42%. The company reported a net loss of $127.09 million and an operating loss of $97.53 million in the latest period. These figures are well below the industry median for profitability metrics, indicating significant underperformance relative to peers. The company's revenue of $3.64 million is highly concentrated, with no disclosed segment or geographic breakdown. This lack of diversification increases exposure to market-specific risks. The absence of segment data also limits the ability to assess the performance of individual product lines or geographic regions. Looking ahead, the company is expected to continue facing financial challenges. The current fiscal year is projected to see a continuation of losses, with no clear path to profitability in the near term. The company's capital expenditures of -$578,000 are minimal, suggesting limited investment in growth initiatives. The company's risk profile is elevated, with a medium liquidity risk and a key flag indicating that net cash is negative after subtracting total debt. The dilution risk is currently low, but the company's high debt load and negative cash flow could necessitate future equity raises, which would increase dilution risk. The company has not issued any recent equity, and there are no immediate signs of dilution pressure. Recent filings and transcripts indicate that the company is in a development phase, with a focus on research and development in the biotechnology space. However, there are no recent material events or earnings calls that suggest a near-term catalyst for value creation. The company's stock is currently trading at a significant discount to analyst price targets, with a mean target of $14.67 and a median target of $16.00.